Researchers at Weill Cornell Medicine and Roswell Park Comprehensive Cancer Center have genetically engineered CAR T cells that specifically target and kill bladder cancer (BCa) cells. Through their ...

USA: A new systematic review published in the Cochrane Database of Systematic Reviews suggests that blue light-enhanced ...

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target ...

A University of Massachusetts Amherst research team has been awarded up to $3.45 million from the National Institutes of ...

University of Colorado football coach Deion Sanders says he feels like his younger self again after undergoing surgery to ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® ...

Researchers analyzed 1590 proteomes across 8 cancer types and found that biological sex can shape tumor protein abundance, ...

FDA clearance enables initiation of a planned Phase 1 clinical study evaluating local intravesical administration of UGN-501, with patient ...

A new treatment combination - Keytruda plus Padcev - is now approved for use before and after bladder‑removal surgery, ...

Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in ...

Adults diagnosed with muscle-invasive bladder cancer gained a new treatment option on July 10, 2026, when the FDA cleared the ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced ...